Tight regulation of retinoic acid (RA) distribution in the embryo is critical for normal morphogenesis. The RA-metabolizing enzymes Cyp26A1 and Cyp26B1 are believed to play important roles in protecting certain embryonic tissues from inappropriate RA signaling. We have cloned the murine Cyp26B1 cDNA and compared its expression pattern to that of Cyp26A1 from embryonic day (E) E7±E11.5 using in situ hybridization. Northern blot analysis shows the presence of two Cyp26B1 transcripts of approximately 2.3 and 3.5 kb in embryonic limb bud. Whereas Cyp26A1 is expressed in gastrulating embryos by E7, Cyp26B1 is ®rst expressed at E8.0 in prospective rhombomeres 3 and 5. Cyp26B1 expression expands to speci®c dorso-ventral locations in rhombomeres 2±6 between E8.5 and E9.5, whereas Cyp26A1 hindbrain expression is limited to rhombomere 2 at E8.5. No (or very weak) Cyp26B1 expression is observed in the tail bud, a major site of Cyp26A1 expression. Differential expression is seen in branchial arches, with Cyp26A1 being mainly expressed in neural crest-derived mesenchyme, and Cyp26B1 in speci®c ectodermal and endodermal areas. Cyp26B1 is markedly expressed in the ectoderm and distal mesoderm of the limb buds from the beginning of their outgrowth. Cyp26A1 transcripts are seen later and at lower levels in limb ectoderm, and both transcripts are excluded from the apical ectodermal ridge. q
Retinoic acid (RA), an active metabolite of vitamin A, is a critical signaling molecule during vertebrate development (reviewed by Maden, 1998) . Maternal vitamin A de®ciency (Wilson et al., 1953; Maden, 1998; White et al., 2000a) , or teratogenic RA excess (Mulder et al., 2000; Maden, 1998 and references therein) results in a spectrum of congenital abnormalities. Thus, embryonic RA levels must be strictly controlled.
In vivo, RA is generated in a tissue-speci®c manner due to differential expression of three retinaldehyde dehydrogenases, RALDH-1, RALDH-2 and RALDH-3 (Zhao et al., 1996; Niederreither et al., 1997; Haselbeck et al., 1999; Li et al., 2000; Mic et al., 2000 and references therein) . Regions of the embryo expressing Raldh genes coincide with those which have been shown to contain RA (Rossant et al., 1991; Mendelsohn et al., 1992; Maden et al., 1998) , and embryos lacking RALDH-2 suffer early morphogenetic defects (Niederreither et al., 1999) .
Certain embryonic regions that appear devoid of RA (Rossant et al., 1991; Mendelsohn et al., 1992) express the RA-degrading enzyme Cyp26A1 (McCaffery et al., 1999; Iulianella et al., 1999) , a novel cytochrome p450 that metabolizes RA into 4-hydroxy and 4-oxo metabolites (White et al., 1996 (White et al., , 1997 Abu-Abed et al., 1998; Fujii et al., 1997; Swindell et al., 1999; Holleman et al., 1998) . Cyp26A1 knockout mice die during mid-late gestation and exhibit caudal regression, spina bi®da, sirenomelia, as well as hindbrain patterning defects and vertebral transformations (AbuAbed et al., 2001; Sakai et al., 2001) .
Cyp26B1 was recently characterized in human as a Cyp26A1 homolog of comparable enzymatic activity (White et al., 2000b) . We have now cloned its murine counterpart and analyzed its mRNA distribution. We show that the two genes are expressed in essentially distinct domains during early embryogenesis (E7±E11.5). Thus, the complex spatio-temporal expression patterns of RA-synthesizing and degrading enzymes may provide a combinatorial mechanism for generating morphogenetic cues.
Results

Identi®cation of mouse CYP26B1
Full length murine Cyp26B1 was ampli®ed by reverse transcription polymerase chain reaction (RT-PCR), using E11.5 limb bud RNA as template (see Section 3). The 1539 base pair murine cDNA shows 93% amino acid identity with human Cyp26B1, and 43% with both human and mouse Cyp26A1 (Fig. 1) .
Northern blot analysis of poly(A 1 ) E11.5 limb bud RNA, hybridized with a murine Cyp26B1 cDNA probe, revealed a doublet with transcript sizes of approximately 2.3 and 3.5 kb (Fig. 2). 1.2. Expression at E7.0±E7.5
Cyp26A1 expression appears by E6.5±E7.0 in the extraembryonic and embryonic endoderm, and then in primitive streak and posterior mesoderm (Fujii et al., 1997; de Roos et al., 1999) . Transient expression is seen in anterior headfold tissues by E7.0±E7.5 (Fig. 3A) . We also observed Cyp26A1 expression at E7.5 within the cardiac crescent and lateral vascular embryonic network, as well as in the allantoic network (Fig. 4A,B) . In contrast, Cyp26B1 transcripts were not detected in E7.0±E7.5 embryos (Fig. 3B ).
1.3. Expression at E8.0±E8.5
Cyp26A1 expression in tailbud mesoderm and posterior neural plate has been documented (Fujii et al., 1997; Fig. 3C,E) . We found that Cyp26A1 expression is spatially restricted in the E8.0 heart tube endocardium, both rostrally in the out¯ow tract and caudally in the atria and sinus venosus, from which labeling extends in the lateral vascular networks (Fig. 4C) . Expression is still seen in the endocardium, but not in other vascular elements, by E8.5±E9 (Figs. 3E and 5A,G, and data not shown; Moss et al., 1998) .
Cyp26B1 expression is initiated at E8.0 in prospective rhombomere 3 and at higher levels in pre-rhombomere 5 (Fig. 3D ). Rhombomeric expression expands as soon as the embryos have turned ( Fig. 3F ; see below). When compared to Cyp26A1, which is transiently expressed in rhombomere 2 by E8.5 (Fujii et al., 1997) , Cyp26B1 hindbrain expression is more intense (compare Fig. 3E and F) . In contrast to Cyp26A1, Cyp26B1 transcripts are not detected in the tail bud region (compare Fig. 3C ,E and D,F). Extended staining reveals Cyp26B1 expression between Cyp26A1 expression is observed in the posterior-most mesoderm and neuroepithelium. Cyp26B1 is detected in developing rhombomeres 3 and 5. (E,F) E8.5, lateral views. Strong Cyp26A1 expression is seen in posterior mesoderm and neuroepithelium. Weak expression in rhombomere 2, mandibular arch and heart out¯ow tract is also evident (arrowheads). Cyp26B1 expression has appeared in rhombomere 6, as well as in the caudal pharyngeal arch region (arrowhead) and intersomitic regions (see higher magni®cation in inset). A, anterior; hf, headfold; md, mandibular arch; ot, out¯ow tract; P, posterior; r2±r6, rhombomeres 2±6; ve, visceral endoderm. the developing somites and at the level of caudal branchial arches (Fig. 3F) , whereas Cyp26A1 expression is observed in the rostral portion of the mandibular arch (Fig. 3E ).
Expression at E9.5±E10.5
Cyp26B1 hindbrain expression has become more complex at E9.5. Highest expression is seen in rhombomeres 5 and 6, while expression appears weaker in rhombomere 3, and non-uniform in rhombomeres 2 and 4 (Fig. 5D) . Hindbrain¯atmounts show expression throughout rhombomeres 5±6 and in the ventral portion (basal plate) of rhombomeres 2±4, the¯oor plate being unlabeled (Fig. 6A) . Three longitudinal columns are labeled in rhombomere 4. The same columnar arrangement becomes apparent in rhombomeres 5±6 by E10.5 (Fig. 6B) .
Cyp26A1 expression in cervical and branchial arch mesenchyme has been reported (Fujii et al., 1997; de Roos et al., 1999 ; Fig. 5C ,E,G). In contrast, Cyp26B1 branchial expression is observed in both ectodermal and endodermal portions of the caudal branchial arches (Fig. 5F ). Only Cyp26A1 is expressed along the maxillo-mandibular cleft (compare Fig. 5E and F) . Cyp26B1 expression was not seen in the growing tail tip, where Cyp26A1 expression is maintained (compare Fig. 5A,G and B,H) . Prolonged stain- Fig. 4 . Details of Cyp26A1 expression in E7.5 (A,B) cranial and caudal views, respectively, and E8.0 (C) embryos. Speci®c expression is seen along the cardiac crescent and developing embryonic and allantoic vascular networks at E7.5, and in the out¯ow tract and atria/sinus venosus regions of the heart at E8.0. Note that signal is comparatively much higher in the posterior region of the embryo. A, atrium; al, allantois; cc, cardiac crescent; hf, headfold; lv, lateral vascular network; ot, out¯ow tract; pm, posterior mesoderm; ps, primitive streak; sv, sinus venosus; v, ventricle. (A,B) E9.5, lateral views. Cyp26A1 is expressed in cervical mesenchyme, tailbud mesoderm and neuroepithelium (arrowhead). Cyp26B1 is expressed in rhombomeres 2±6, forelimb bud and developing hindlimb bud (indicated by arrowhead). (C,D) E9.5, dorsal views of the hindbrain region. Cyp26A1 expression is no longer seen in the hindbrain, but is present in the adjacent cervical mesenchyme, laterally and caudally to the otic vesicle (arrowheads). Cyp26B1 is differentially expressed in rhombomeres 2±6. (E,F) E9.5, details of the branchial arch labeling patterns. Cyp26A1 expression in cervical mesenchyme enccompasses the second arch and is also seen in the caudal region of the ®rst arch. Restricted signal is also seen along the maxillo-mandibular cleft. In contrast, Cyp26B1 expression is observed in de®ned areas of the caudal branchial arches (arrowheads). Histological analysis (inset) shows labeling along the inner (endodermal, left) and outer (ectodermal, right) edges of the branchial arches. (G,H) E10.5, lateral views. Cyp26A1 expression persists in tailbud (arrowhead) and cervical mesenchyme. Cyp26B1 expression is restricted to the hindbrain (note that transcripts now extend towards the met-mesencephalic boundary, arrowhead) and limb buds. b2, second branchial arch; cm, cervical mesenchyme; , forelimb; hl, hindlimb; md, mandibular process of the ®rst branchial arch; r2±r6, rhombomeres; ov, otic vesicle. At this stage, Cyp26A1 expression in the branchial region is more restricted than that of Cyp26B1, which has expanded up to the ®rst arch, and has also appeared in the nasal process. Cyp26B1 expression at the level of the met-mesencephalic boundary (arrowhead) has become stronger than within the hindbrain. Cyp26B1 expression remains prominent in the developing limbs. (C±F) High magni®cation views of the forelimb extremity (handplate). Cyp26B1 is highly expressed along the distal margin of the developing handplate, except for the AER (D,F). Although Cyp26A1 limb expression is markedly weaker (C,E), two labeled stripes can be distinguished along each side of the ridge (arrowheads). AER, apical ectodermal ridge;¯, forelimb; hl, hindlimb; md, mandibular process; mx, maxillary process; np, nasal process.
ing revealed weak Cyp26B1 signal in tail bud mesoderm, indicating co-expression with Cyp26A1, albeit at much lower levels (not shown).
Cyp26B1 expression is detected in limb buds at outgrowth (Fig. 5B,H) . Expression ®rst appears along the ventral aspect of the buds (Fig. 7A,B) . Shortly thereafter, expression expands dorsally, but remains weak in the central region where the apical ectodermal ridge (AER) will develop (Fig. 7C,E) . On sections, expression appears restricted to the ectoderm and/or super®cial mesenchyme (Fig. 7F) . Cyp26B1 transcripts are distally restricted during further limb outgrowth (Fig. 7D) . By E10.5, expression occurs throughout the distal mesenchyme or progress zone, but remains highest along the dorsal and ventral aspects (Fig. 7G) . Cyp26A1 transcripts were not detected in limbs at these stages (see Fig. 5A ,G).
Expression at E11.5
Cyp26A1 expression has been described in the maxillomandibular cleft region (Fig. 8A ) and the neural retina (not shown; Fujii et al., 1997; McCaffery et al., 1999) . Cyp26B1 expression is not detected in neural retina (not shown). Cyp26B1 expression has decreased in the caudal hindbrain (myelencephalon), whereas expression in the met-mesencephalic region (®rst seen in E10.5 embryos) has increased (Figs. 5H and 8B, arrowheads). Cyp26B1 expression has also expanded in maxillary and mandibular components of the ®rst branchial arch, as well as in the second arch (Fig.  8B) . Furthermore, expression has appeared within the developing nasal process (Fig. 8B) . In the limbs, Cyp26B1 expression remains strong along the distal margin of the footplates (Fig. 8B,D) , but is excluded from the AER (Fig. 8F ). Cyp26A1 expression is detected at lower levels in two stripes¯anking the AER (Fig. 8C,E, arrowheads) .
Materials and methods
RNA extraction, RT-PCR and Northern blotting
Total RNA from E11.5 fore-and hindlimb buds (30 embryos) was extracted with TRIzol (Gibco, BRL, Grand Island, NY, USA). Two mouse expressed sequence tags (ESTs) (Genbank AW488377, AW047279) highly homologous to human Cyp26B1 were used to design PCR primers (sense 5 H -ATGCTGTTTGAAGG CTTGGAGTTG, antisense 5 H -CTACACCGTAGCACTCAACATGGC). RT-PCR was performed using the ThermoScripte RT-PCR System (Gibco, BRL) and TakaraExTaqe Polymerase (TaKaRa Biomedicals, Kyoto, Japan).
Poly (A) 1 RNA was prepared from limb bud RNA using an Oligotex kit (Qiagen, Mississauga, ON, Canada), and 2 mg was run on an agarose/formamide gel, transferred to Hybond-N1 (Amersham Pharmacia Biotech, Baie d'Urfe Â, PQ, Canada) and hybridized as described by Abu-Abed et al. (1998) . The Cyp26B1 probe used spanned putative exons 2±5.
Whole-mount in situ hybridization
An RNA labeling kit (Roche, Lavel, PQ, Canada) was used to synthesize Cyp26A1 and Cyp26B1 antisense riboprobes from plasmids containing full length cDNA and exons 2±5, respectively. In situ hybridization was performed on CD-1 (Caesarean Derived) mouse embryos (Charles River, ON, Canada) as described by De Âcimo et al. (1995) and Niederreither et al. (1997) . Some of the hybridized embryos were post-®xed in 2.5% glutaraldehyde and embedded using the JB-4 embedding kit (Polysciences, Warrington, PA, USA) for sectioning.
